138 related articles for article (PubMed ID: 11071705)
1. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
2. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
3. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
5. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Crocker SJ; Wigle N; Liston P; Thompson CS; Lee CJ; Xu D; Roy S; Nicholson DW; Park DS; MacKenzie A; Korneluk RG; Robertson GS
Eur J Neurosci; 2001 Jul; 14(2):391-400. PubMed ID: 11553289
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
7. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft.
Baker KA; Sadi D; Hong M; Mendez I
J Comp Neurol; 2000 Oct; 426(1):106-16. PubMed ID: 10980486
[TBL] [Abstract][Full Text] [Related]
9. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
Deumens R; Blokland A; Prickaerts J
Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
[TBL] [Abstract][Full Text] [Related]
11. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat.
Martí MJ; Saura J; Burke RE; Jackson-Lewis V; Jiménez A; Bonastre M; Tolosa E
Brain Res; 2002 Dec; 958(1):185-91. PubMed ID: 12468044
[TBL] [Abstract][Full Text] [Related]
12. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Meshul CK; Allen C
Synapse; 2000 May; 36(2):129-42. PubMed ID: 10767060
[TBL] [Abstract][Full Text] [Related]
13. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine.
Rodrigues RW; Gomide VC; Chadi G
Int J Neurosci; 2001 Jul; 109(1-2):91-126. PubMed ID: 11699344
[TBL] [Abstract][Full Text] [Related]
14. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Melamed E; Hefti F; Wurtman RJ
Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
[TBL] [Abstract][Full Text] [Related]
15. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats.
Bowyer JF; Frame LT; Clausing P; Nagamoto-Combs K; Osterhout CA; Sterling CR; Tank AW
J Pharmacol Exp Ther; 1998 Aug; 286(2):1074-85. PubMed ID: 9694971
[TBL] [Abstract][Full Text] [Related]
17. Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion.
Tsuboi K; Kimber TA; Shults CW
Brain Res; 2000 Jun; 866(1-2):55-64. PubMed ID: 10825480
[TBL] [Abstract][Full Text] [Related]
18. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes.
Revuelta M; Venero JL; Machado A; Cano J
Glia; 1997 Oct; 21(2):204-16. PubMed ID: 9336235
[TBL] [Abstract][Full Text] [Related]
19. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain.
Blanchard V; Chritin M; Vyas S; Savasta M; Feuerstein C; Agid Y; Javoy-Agid F; Raisman-Vozari R
J Neurochem; 1995 Apr; 64(4):1669-79. PubMed ID: 7891094
[TBL] [Abstract][Full Text] [Related]
20. Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system.
Nakamura K; Won L; Heller A; Kang UJ
Brain Res; 2000 Aug; 873(2):203-11. PubMed ID: 10930545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
